Valirx wins Canadian patent for 'gene-silencing' technology
ValiRx, the AIM listed life sciences firm, saw its share price surge on news that its 'gene-silencing' technology has received patent approval in Canada.
ValiRx, the AIM listed life sciences firm, saw its share price surge on news that its 'gene-silencing' technology has received patent approval in Canada.
It already has patents for the US, Europe and Australia.
ValiRx is developing treatments which "silence" so called rebellious genes that can cause cancer and various neurological problems.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The firm also announced today that it has extended its agreement with Imperial College London for cancer therapeutic work.
Production of ValiRx's main "VAL101" compound is "going to plan and has been optimised and simplified." The company argues this will reduce costs and add future value.
Dr. Satu Vainikka, ValiRx's Chief Executive, said of the patent grant: "The filing of this latest patent extends our global geographic patent coverage and I believe it represents a value marker for the company, as we further progress the GeneICE pre-clinical programme."
At 9:13am shares in the company were at 0.502p, a rise of 14.2% on the day. This year ValiRx has seen its value rise 99%.
BS
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
Trump’s tariffs: what is he thinking and how should UK respond?
Every right-thinking person knows that free trade is a surer route to the wealth of nations than protectionism, says Stuart Watkins. What is Trump thinking?
By Stuart Watkins Published
-
Barclays begins paying up to £100 compensation to customers after banking outage
Barclays will pay up to £7.5 million in compensation to customers after its banking services were disrupted by an IT outage
By Daniel Hilton Published